About Anthera
Anthera is a publicly listed company based in Hayward (United States) founded in 2004. Therapeutics are developed for inflammatory, cardiovascular, and autoimmune diseases. Anthera has raised $55 million across 3 funding rounds from investors including Mitsubishi Corporation, VantagePoint Capital Partners and Sofinnova. Its chief executive, as recorded, is Craig Thompson. Anthera offers products and services including Vernis Soin and Le Bouquet. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is ANTHERA PHARMACEUTICALS, INC. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Anthera was founded in 2004 and is headquartered in Hayward, United States. Operations center on the development and commercialization of therapeutics targeting inflammation, cardiovascular conditions, and autoimmune diseases. The pipeline features the Sollpura program, addressing exocrine pancreatic insufficiency in phase 3 trials with capsule and powder forms; the Lipibimod program for systemic lupus erythematosus in phase 3; and a phase 2 candidate for IgA nephropathy.
- Headquarters Hayward, United States
- Stage Public
- SectorsHealthcare
- Website anthera.com
- Social LinkedIn X Instagram YouTube
- Legal Name Anthera Pharmaceuticals Inc
- Total Equity Funding$55M (USD)
in 3 rounds
- Latest Funding Round$15M (USD), Post-IPO
Jan 2018
- InvestorsMitsubishi Corporation
& 4 more
Products & Services of Anthera
Anthera offers a comprehensive portfolio of products and services, including Vernis Soin and Le Bouquet.
Protects, fortifies, and hydrates nails using natural oils.
Set of five vernis with a free one for nail care.
Apps and channels of Anthera
its YouTube channel Anthera | Le Maquillage Soin has 2 subscribers and 1 videos.
Videos from Anthera
The most watched videos on Anthera's YouTube channel, Anthera | Le Maquillage Soin (2 subscribers). Click a video to play it here.
More on Anthera | Le Maquillage Soin.
Funding Insights of Anthera
Anthera has successfully raised a total of $55M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 3
- Last Round Post-IPO — $15M
- First Round $36M
(Sep 2006)
- Investors Count 5
All 3 funding rounds of Anthera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $15M | Post-IPO | – | – | – |
| Aug 2008 | $19M | Private Equity Round | – | – | – |
| Sep 2006 | $36M | Series A | – | VantagePoint Capital Partners, Sofinnova Investments |
5 investors in total: 5 institutional.
Investors in Anthera
Anthera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Mitsubishi Corporation, VantagePoint Capital Partners and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm | vpcp.com | Santa Barbara, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
A venture investment firm focused on life sciences is operated. | 1994 | searscapital.net | ||
Natural gas and petroleum are distributed and traded globally. | 1954 | mitsubishicorp.com | New York, United States |
Investor details for Anthera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anthera
1 people are tracked at Anthera (1 in leadership).
| Name | Role | Group |
|---|---|---|
Craig Thompson | CEO | Leadership |
Complete people profiles for Anthera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Anthera
Anthera is a publicly listed company on the OTC with ticker symbol ANTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Mar 2010
- Listed onNASDAQ: ANTH
- Listed entityANTHERA PHARMACEUTICALS INC
- Exchange sectorHealth technology
- ISINUS03674U3005
- Share price$0.00 (+35% on the day) · 2026-10-08
- Market capitalisation$3,534.21
- Volume (last session)149
Timeline of Anthera
4 dated milestones of Anthera across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Anthera is founded.
- Funding First funding round of $36.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
Competitors of Anthera
Anthera has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of Anthera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Anthera
Websites that share an audience with Anthera (anthera.com).
Websites whose visitors overlap most with Anthera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aradigm.com | 100% | View details | |||
| apricusbio.com | 98% | View details | |||
iderapharma.com | iderapharma.com | 91% | – | ||
| deciphera.com | 91% | 12.2K | #2,044,202 | View details | |
| luitpold.com | 90% | 1K | #15,337,585 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Anthera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Anthera (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anthera
Complete news archive for Anthera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anthera
Anthera was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Anthera is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Craig Thompson is the CEO of Anthera, as recorded in our data.
Anthera is a funded company, having raised a total of $55M across 3 funding rounds to date. The company's 1st funding round was a Series A of $36M, raised on Sep 2006.
Anthera was founded in 2004 and is headquartered in Hayward, United States. Operations center on the development and commercialization of therapeutics targeting inflammation, cardiovascular conditions, and autoimmune diseases. The pipeline features the Sollpura program, addressing exocrine pancreatic insufficiency in phase 3 trials with capsule and powder forms; the Lipibimod program for systemic lupus erythematosus in phase 3; and a phase 2 candidate for IgA nephropathy.
Anthera's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Anthera offers Vernis Soin and Le Bouquet.
Yes, Anthera is publicly traded on OTC under the ticker symbol ANTH.
Anthera has 5 investors. Key investors include Mitsubishi Corporation, VantagePoint Capital Partners, Sofinnova, Pappas Capital, and Sears Capital Management.
Anthera operates through Anthera Pharmaceuticals, Inc..